{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:00:46Z","timestamp":1791892846011,"version":"4.3.4"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T00:00:00Z","timestamp":1442880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1038\/nrneurol.2015.172","type":"journal-article","created":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T05:49:11Z","timestamp":1442900951000},"page":"567-584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":262,"title":["Monoamine neurotransmitter disorders\u2014clinical advances and future perspectives"],"prefix":"10.1038","volume":"11","author":[{"given":"Joanne","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Papandreou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Heales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju A.","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,22]]},"reference":[{"key":"BFnrneurol2015172_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S1054-3589(08)60806-6","volume":"42","author":"DS Goldstein","year":"1998","unstructured":"Goldstein, D. S. Catecholamines in the periphery. Overview. Adv. Pharmacol. 42, 529\u2013539 (1998).","journal-title":"Adv. Pharmacol."},{"key":"BFnrneurol2015172_CR2","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0024-3205(97)01166-1","volume":"62","author":"O Yildiz","year":"1998","unstructured":"Yildiz, O., Smith, J. R. & Purdy, R. E. Serotonin and vasoconstrictor synergism. Life Sci. 62, 1723\u20131732 (1998).","journal-title":"Life Sci."},{"key":"BFnrneurol2015172_CR3","volume-title":"Congenital Neurotransmitter Disorders: A Clinical Approach","author":"GF Hoffmann","year":"2014","unstructured":"Hoffmann, G. F. & Blau, N. (Eds) Congenital Neurotransmitter Disorders: A Clinical Approach (Nova Science Publishers, 2014)."},{"key":"BFnrneurol2015172_CR4","volume-title":"PND database","author":"N Blau","year":"2015","unstructured":"Blau, N. & Th\u00f6ny, B. PND database [online] (2015)."},{"key":"BFnrneurol2015172_CR5","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.clinbiochem.2005.09.012","volume":"38","author":"PL Pearl","year":"2005","unstructured":"Pearl, P. L., Capp, P. K., Novotny, E. J. & Gibson, K. M. Inherited disorders of neurotransmitters in children and adults. Clin. Biochem. 38, 1051\u20131058 (2005).","journal-title":"Clin. Biochem."},{"issue":"Suppl. 6","key":"BFnrneurol2015172_CR6","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1002\/ana.10628","volume":"54","author":"B Assmann","year":"2003","unstructured":"Assmann, B., Surtees, R. & Hoffmann, G. F. Approach to diagnosis of neurotransmitter diseases exemplified by the differential diagnosis of childhood-onset dystonia. Ann. Neurol. 54 (Suppl. 6), S18\u2013S24 (2003).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2015172_CR7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S1474-4422(11)70141-7","volume":"10","author":"MA Kurian","year":"2011","unstructured":"Kurian, M. A., Gissen, P, Smith, M., Heales, S. Jr & Clayton, P. T. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol. 10, 721\u2013733 (2011).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2015172_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12098-009-0138-6","volume":"76","author":"E Fern\u00e1ndez-Alvarez","year":"2009","unstructured":"Fern\u00e1ndez-Alvarez, E. Movement disorders in children: recent advances in management. Indian J. Pediatr. 76, 531\u2013536 (2009).","journal-title":"Indian J. Pediatr."},{"key":"BFnrneurol2015172_CR9","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.clinbiochem.2008.08.077","volume":"41","author":"I Mar\u00edn-Valencia","year":"2008","unstructured":"Mar\u00edn-Valencia, I. et al. Biochemical diagnosis of dopaminergic disturbance in paediatric patients: analysis of cerebrospinal fluid homovanillic acid and other biogenic amines. Clin. Biochem. 41, 1306\u20131315 (2008).","journal-title":"Clin. Biochem."},{"key":"BFnrneurol2015172_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0006-8993(74)90562-9","volume":"79","author":"E Garelis","year":"1974","unstructured":"Garelis, E., Young, S. N., Lal, S. & Sourkes, T. L. Monoamine metabolites in lumbar CSF: the question of their origin in relation to clinical studies. Brain Res. 79, 1\u20138 (1974).","journal-title":"Brain Res."},{"key":"BFnrneurol2015172_CR11","first-page":"35","volume-title":"Neurology and Psychiatry","author":"H McConnell","year":"1994","unstructured":"McConnell, H. & Bianchine, J. Cerebrospinal fluid. in Neurology and Psychiatry. Ch. 3 35\u201342 (Chapman & Hall Medical, 1994)."},{"key":"BFnrneurol2015172_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1023\/A:1016550324235","volume":"25","author":"C Br\u00e4utigam","year":"2002","unstructured":"Br\u00e4utigam, C., Weykamp, C., Hoffmann, G. F. & Wevers, R. A. Neurotransmitter metabolites in CSF: an external quality control scheme. J. Inherit. Metab. Dis. 25, 287\u2013298 (2002).","journal-title":"J. Inherit. Metab. Dis."},{"key":"BFnrneurol2015172_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1203\/00006450-199307000-00003","volume":"34","author":"K Hyland","year":"1993","unstructured":"Hyland, K. et al. Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population. Pediatr. Res. 34, 10\u201314 (1993).","journal-title":"Pediatr. Res."},{"key":"BFnrneurol2015172_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.braindev.2010.10.015","volume":"33","author":"M Segawa","year":"2011","unstructured":"Segawa, M. Hereditary progressive dystonia with marked diurnal fluctuation. Brain Dev. 33, 195\u2013201 (2011).","journal-title":"Brain Dev."},{"key":"BFnrneurol2015172_CR15","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s10545-012-9506-x","volume":"35","author":"T Opladen","year":"2012","unstructured":"Opladen, T., Hoffmann, G. F. & Blau, N. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. J. Inherit. Metab. Dis. 35, 963\u2013973 (2012).","journal-title":"J. Inherit. Metab. Dis."},{"key":"BFnrneurol2015172_CR16","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/brain\/awq087","volume":"133","author":"MA Willemsen","year":"2010","unstructured":"Willemsen, M. A. et al. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 133, 1810\u20131822 (2010).","journal-title":"Brain"},{"key":"BFnrneurol2015172_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.braindev.2005.10.012","volume":"28","author":"WL Yeung","year":"2006","unstructured":"Yeung, W. L., Lam, C. W., Hui, J., Tong, S. F. & Wu, S. P. Galactorrhea\u2014a strong clinical clue towards the diagnosis of neurotransmitter disease. Brain Dev. 28, 389\u2013391 (2006).","journal-title":"Brain Dev."},{"key":"BFnrneurol2015172_CR18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1258\/acb.2012.012080","volume":"50","author":"H Aitkenhead","year":"2013","unstructured":"Aitkenhead, H. & Heales, S. J. Establishment of paediatric age-related reference intervals for serum prolactin to aid in the diagnosis of neurometabolic conditions affecting dopamine metabolism. Ann. Clin. Biochem. 50, 156\u2013158 (2013).","journal-title":"Ann. Clin. Biochem."},{"key":"BFnrneurol2015172_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1212\/WNL.0b013e3181e620ae","volume":"75","author":"L Brun","year":"2010","unstructured":"Brun, L. et al. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology 75, 64\u201371 (2010).","journal-title":"Neurology"},{"key":"BFnrneurol2015172_CR20","first-page":"1595","volume":"119","author":"MA Kurian","year":"2009","unstructured":"Kurian, M. A. et al. Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism\u2013dystonia. J. Clin. Invest. 119, 1595\u20131603 (2009).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol2015172_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S1474-4422(10)70269-6","volume":"10","author":"MA Kurian","year":"2011","unstructured":"Kurian, M. A. et al. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol. 10, 54\u201362 (2011).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2015172_CR22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa1207281","volume":"368","author":"JJ Rilstone","year":"2013","unstructured":"Rilstone, J. J., Alkhater, R. A. & Minassian, B. A. Brain dopamine\u2013serotonin vesicular transport disease and its treatment. N. Engl. J. Med. 368, 543\u2013550 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2015172_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ymgme.2004.07.010","volume":"83","author":"R Saunders-Pullman","year":"2004","unstructured":"Saunders-Pullman, R. et al. Phenylalanine loading as a diagnostic test for DRD: interpreting the utility of the test. Mol. Genet. Metab. 83, 207\u2013212 (2004).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrneurol2015172_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1023\/A:1005398406988","volume":"21","author":"P Guldberg","year":"1998","unstructured":"Guldberg, P., Henriksen, K. F., Lou, H. C. & G\u00fcttler, F. Aberrant phenylalanine metabolism in phenylketonuria heterozygotes. J. Inherit. Metab. Dis. 21, 365\u2013372 (1998).","journal-title":"J. Inherit. Metab. Dis."},{"key":"BFnrneurol2015172_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ymgme.2013.01.001","volume":"108","author":"T Opladen","year":"2013","unstructured":"Opladen, T., Hoffmann, G. F, K\u00fchn, A. A. & Blau, N. Pitfalls in phenylalanine loading test in the diagnosis of dopa-responsive dystonia. Mol. Genet. Metab. 108, 195\u2013197 (2013).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrneurol2015172_CR26","first-page":"1","volume":"32","author":"M Segawa","year":"2009","unstructured":"Segawa, M. Autosomal dominant GTP cyclohydrolase 1 (AD GCH 1) deficiency (Segawa disease, dystonia 5; DYT 5). Chang Gung Med. J. 32, 1\u201311 (2009).","journal-title":"Chang Gung Med. J."},{"key":"BFnrneurol2015172_CR27","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/ana.22685","volume":"71","author":"J Friedman","year":"2012","unstructured":"Friedman, J. et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann. Neurol. 71, 520\u2013530 (2012).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2015172_CR28","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/brain\/awp084","volume":"132","author":"F Clot","year":"2009","unstructured":"Clot, F. et al. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain 132, 1753\u20131763 (2009).","journal-title":"Brain"},{"key":"BFnrneurol2015172_CR29","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/mds.25382","volume":"28","author":"R Pons","year":"2013","unstructured":"Pons, R. et al. Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency. Mov. Disord. 28, 1058\u20131063 (2013).","journal-title":"Mov. Disord."},{"key":"BFnrneurol2015172_CR30","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.pediatrneurol.2012.03.003","volume":"46","author":"E L\u00f3pez-Laso","year":"2012","unstructured":"L\u00f3pez-Laso, E., Beyer, K., Opladen, T., Artuch, R. & Saunders-Pullman, R. Dyskinesias as a limiting factor in the treatment of Segawa disease. Pediatr. Neurol. 46, 404\u2013406 (2012).","journal-title":"Pediatr. Neurol."},{"key":"BFnrneurol2015172_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1399-0004.2009.01306.x","volume":"77","author":"V Leuzzi","year":"2010","unstructured":"Leuzzi, V. et al. Phenotypic variability, neurological outcome and genetics background of 6-pyruvoyl-tetrahydrobiopterin synthase deficiency. Clin. Genet. 77, 249\u2013257 (2010).","journal-title":"Clin. Genet."},{"key":"BFnrneurol2015172_CR32","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/brain\/awu022","volume":"137","author":"J Ng","year":"2014","unstructured":"Ng, J. et al. Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain 137, 1107\u20131119 (2014).","journal-title":"Brain"},{"key":"BFnrneurol2015172_CR33","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1196\/annals.1296.064","volume":"1018","author":"HJ Timmers","year":"2004","unstructured":"Timmers, H. J., Deinum, J., Wevers, R. A. & Lenders, J. W. Congenital dopamine-\u03b2-hydroxylase deficiency in humans. Ann. N. Y. Acad. Sci. 1018, 520\u2013523 (2004).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"BFnrneurol2015172_CR34","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","volume":"376","author":"N Blau","year":"2010","unstructured":"Blau, N., van Spronsen, F. J. & Levy, H. L. Phenylketonuria. Lancet 376, 1417\u20131427 (2010).","journal-title":"Lancet"},{"key":"BFnrneurol2015172_CR35","volume-title":"GeneReviews","author":"Y Furukawa","year":"2015","unstructured":"Furukawa, Y. GTP cyclohydrolase 1-deficient dopa-responsive dystonia. GeneReviews [online] (updated 2015)."},{"key":"BFnrneurol2015172_CR36","first-page":"215","volume":"14","author":"M Segawa","year":"1976","unstructured":"Segawa, M., Hosaka, A., Miyagawa, F., Nomura, Y. & Imai, H. Hereditary progressive dystonia with marked diurnal fluctuation. Adv. Neurol. 14, 215\u2013233 (1976).","journal-title":"Adv. Neurol."},{"key":"BFnrneurol2015172_CR37","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/jnnp.2008.155861","volume":"80","author":"I Trender-Gerhard","year":"2009","unstructured":"Trender-Gerhard, I. et al. Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J. Neurol. Neurosurg. Psychiatry 80, 839\u2013845 (2009).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2015172_CR38","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3346\/jkms.2011.26.9.1244","volume":"26","author":"JH Lee","year":"2011","unstructured":"Lee, J. H., Ki, C. S., Kim, D. S., Cho, J. W., Park, K. P. & Kim, S. Dopa-responsive dystonia with a novel initiation codon mutation in the GCH1 gene misdiagnosed as cerebral palsy. J. Korean Med. Sci. 26, 1244\u20131246 (2011).","journal-title":"J. Korean Med. Sci."},{"key":"BFnrneurol2015172_CR39","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.pediatrneurol.2004.03.017","volume":"31","author":"MM Jan","year":"2004","unstructured":"Jan, M. M. Misdiagnoses in children with dopa-responsive dystonia. Pediatr. Neurol. 31, 298\u2013303 (2004).","journal-title":"Pediatr. Neurol."},{"key":"BFnrneurol2015172_CR40","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1469-8749.2010.03619.x","volume":"52","author":"RC Dale","year":"2010","unstructured":"Dale, R. C. et al. Familial paroxysmal exercise-induced dystonia: atypical presentation of autosomal dominant GTP-cyclohydrolase 1 deficiency. Dev. Med. Child Neurol. 52, 583\u2013586 (2010).","journal-title":"Dev. Med. Child Neurol."},{"key":"BFnrneurol2015172_CR41","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1093\/brain\/awu179","volume":"137","author":"NE Mencacci","year":"2014","unstructured":"Mencacci, N. E. et al. Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain 137, 2480\u20132492 (2014).","journal-title":"Brain"},{"key":"BFnrneurol2015172_CR42","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.parkreldis.2015.01.004","volume":"21","author":"AJ Lewthwaite","year":"2015","unstructured":"Lewthwaite, A. J. et al. Novel GCH1 variant in Dopa-responsive dystonia and Parkinson's disease. Parkinsonism Relat. Disord. 21, 394\u2013397 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"BFnrneurol2015172_CR43","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/humu.20366","volume":"27","author":"B Th\u00f6ny","year":"2006","unstructured":"Th\u00f6ny, B & Blau, N. Mutations in the BH4-metabolizing genes GTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase. Hum. Mutat. 27, 870\u2013878 (2006).","journal-title":"Hum. Mutat."},{"key":"BFnrneurol2015172_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10048-006-0069-6","volume":"8","author":"D Steinberger","year":"2007","unstructured":"Steinberger, D. et al., Utility of MLPA in deletion analysis of GCH1 in dopa-responsive dystonia. Neurogenetics 8, 51\u201355 (2007).","journal-title":"Neurogenetics"},{"key":"BFnrneurol2015172_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1353-8020(00)00084-5","volume":"8","author":"WJ Hwang","year":"2001","unstructured":"Hwang, W. J., Calne, D. B., Tsui, J. K. & de la Fuente-Fern\u00e1ndez, R. The long-term response to levodopa in dopa-responsive dystonia. Parkinsonism Relat. Disord. 8, 1\u20135 (2001).","journal-title":"Parkinsonism Relat. Disord."},{"key":"BFnrneurol2015172_CR46","doi-asserted-by":"publisher","first-page":"41150","DOI":"10.1074\/jbc.M102237200","volume":"276","author":"C Sumi-Ichinose","year":"2001","unstructured":"Sumi-Ichinose, C. et al. Catecholamines and serotonin are differently regulated by tetrahydrobiopterin. A study from 6-pyruvolytetrahydrobiopterin synthase knockout mice. J. Biol. Chem. 276, 41150\u201341160 (2001).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2015172_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mds.23329","volume":"26","author":"T Opladen","year":"2011","unstructured":"Opladen, T. et al. Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. Mov. Disord. 26, 157\u2013161 (2011).","journal-title":"Mov. Disord."},{"key":"BFnrneurol2015172_CR48","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/clinchem\/47.3.477","volume":"47","author":"L Bonaf\u00e9","year":"2001","unstructured":"Bonaf\u00e9, L., Th\u00f6ny, B., Leimbacher, W., Kierat, L. & Blau, N. Diagnosis of dopa-responsive dystonia and other tetrahydrobiopterin disorders by the study of biopterin metabolism in fibroblasts. Clin. Chem. 47, 477\u2013485 (2001).","journal-title":"Clin. Chem."},{"key":"BFnrneurol2015172_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ymgme.2008.01.003","volume":"94","author":"GA Horvath","year":"2008","unstructured":"Horvath, G. A. et al. Autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia: evidence of a phenotypic continuum between dominant and recessive forms. Mol. Genet. Metab. 94, 127\u2013131 (2008).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrneurol2015172_CR50","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10545-009-1067-2","volume":"32","author":"N Longo","year":"2009","unstructured":"Longo, N. Disorders of biopterin metabolism. J. Inherit. Metab. Dis. 32, 333\u2013342 (2009).","journal-title":"J. Inherit. Metab. Dis."},{"key":"BFnrneurol2015172_CR51","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/S0140-6736(85)91474-6","volume":"325","author":"I Smith","year":"1985","unstructured":"Smith, I. & Dhondt, J. L. Birthweight in patients with defective biopterin metabolism. Lancet 325, 818 (1985).","journal-title":"Lancet"},{"key":"BFnrneurol2015172_CR52","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ymgme.2007.10.004","volume":"93","author":"L J\u00e4ggi","year":"2008","unstructured":"J\u00e4ggi, L. et al. Outcome and long-term follow up of 36 patients with tetrahydrobiopterin deficiency. Mol. Genet. Metab. 93, 295\u2013305 (2008).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrneurol2015172_CR53","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1212\/WNL.0b013e3181b38983","volume":"73","author":"F Porta","year":"2009","unstructured":"Porta, F., Mussa, A., Concolino, D., Spada, M. & Ponzone, A. Dopamine agonists in 6-pyruvoyl tetrahydrobiopterin synthase deficiency. Neurology 73, 633\u2013637 (2009).","journal-title":"Neurology"},{"key":"BFnrneurol2015172_CR54","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1212\/WNL.0b013e3182452849","volume":"78","author":"P Dill","year":"2012","unstructured":"Dill, P. et al. Child neurology: paroxysmal stiffening, upward gaze, and hypotonia: hallmarks of sepiapterin reductase deficiency. Neurology 78, e29\u2013e32 (2012).","journal-title":"Neurology"},{"key":"BFnrneurol2015172_CR55","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1212\/01.wnl.0000437299.51312.5f","volume":"81","author":"V Leuzzi","year":"2013","unstructured":"Leuzzi, V. et al. Very early pattern of movement disorders in sepiapterin reductase deficiency. Neurology 81, 2141\u20132142 (2013).","journal-title":"Neurology"},{"key":"BFnrneurol2015172_CR56","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1212\/01.wnl.0000247274.21261.b4","volume":"67","author":"J Friedman","year":"2006","unstructured":"Friedman, J., Hyland, K., Blau, N. & MacCollin, M. Dopa-responsive hypersomnia and mixed movement disorder due to sepiapterin reductase deficiency. Neurology 67, 2032\u20132035 (2006).","journal-title":"Neurology"},{"key":"BFnrneurol2015172_CR57","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1093\/brain\/awh603","volume":"128","author":"BG Neville","year":"2005","unstructured":"Neville, B. G., Parascandalo, R., Farrugia, R. & Felice, A. Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain 128, 2291\u20132296 (2005).","journal-title":"Brain"},{"key":"BFnrneurol2015172_CR58","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1086\/321970","volume":"69","author":"L Bonaf\u00e9","year":"2001","unstructured":"Bonaf\u00e9, L., Th\u00f6ny, B., Penzien, J. M., Czarnecki, B. & Blau, N. Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monamine-neurotransmitter deficiency without hyperphenylalaninemia. Am. J. Hum. Genet. 69, 269\u2013277 (2001).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrneurol2015172_CR59","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1074\/jbc.M805403200","volume":"284","author":"MJ Crabtree","year":"2009","unstructured":"Crabtree, M. J. et al. Quantitative regulation of intracellular endothelial nitric-oxide synthase (eNOS) coupling by both tetrahydrobiopterin\u2013eNOS stoichiometry and biopterin redox status: insights from cells with tet-regulated GTP cyclohydroxylase I expression. J. Biol. Chem. 284, 1136\u20131144 (2009).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2015172_CR60","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s004390050800","volume":"103","author":"B Th\u00f6ny","year":"1998","unstructured":"Th\u00f6ny, B. et al., Mutations in the pterin-4\u03b1-carbinolamine dehydratase (PCBD) gene cause a benign form of hyperphenylalaninemia. Hum. Genet. 103, 162\u2013167 (1998).","journal-title":"Hum. Genet."},{"key":"BFnrneurol2015172_CR61","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1126\/science.1763325","volume":"254","author":"DB Mendel","year":"1991","unstructured":"Mendel, D. B. et al. Characterization of a cofactor that regulates dimerization of a mammalian homeodomain protein. Science 254, 1762\u20131767 (1991).","journal-title":"Science"},{"key":"BFnrneurol2015172_CR62","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1681\/ASN.2013040337","volume":"25","author":"S Ferr\u00e8","year":"2014","unstructured":"Ferr\u00e8, S. et al. Mutations in PCBD1 cause hypomagnesemia and renal magnesium wasting. J. Am. Soc. Nephrol. 25, 574\u2013586 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneurol2015172_CR63","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.2337\/db13-1784","volume":"63","author":"D Simaite","year":"2014","unstructured":"Simaite, D. et al. Recessive mutations in PCBD1 cause a new type of early-onset diabetes. Diabetes 63, 3557\u20133564 (2014).","journal-title":"Diabetes"},{"key":"BFnrneurol2015172_CR64","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ymgme.2009.12.011","volume":"99","author":"CM Mak","year":"2010","unstructured":"Mak, C. M. et al. Biochemical and molecular characterization of tyrosine hydroxylase deficiency in Hong Kong Chinese. Mol. Genet. Metab. 99, 431\u2013433 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrneurol2015172_CR65","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1055\/s-2007-991151","volume":"38","author":"T Giovanniello","year":"2007","unstructured":"Giovanniello, T. et al. Tyrosine hydroxylase deficiency presenting with a biphasic clinical course. Neuropediatrics 38, 213\u2013215 (2007).","journal-title":"Neuropediatrics"},{"key":"BFnrneurol2015172_CR66","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1212\/WNL.0b013e318261714a","volume":"79","author":"M Stamelou","year":"2012","unstructured":"Stamelou, M. et al. Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. Neurology 79, 435\u2013441 (2012).","journal-title":"Neurology"},{"key":"BFnrneurol2015172_CR67","first-page":"1264","volume":"19","author":"AJ Espay","year":"2013","unstructured":"Espay, A. J. & Chen, R. Myoclonus. Continuum (Minneap. Minn.) 19, 1264\u20131286 (2013).","journal-title":"Continuum (Minneap. Minn.)"},{"key":"BFnrneurol2015172_CR68","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ymgme.2014.10.014","volume":"114","author":"C Ortez","year":"2015","unstructured":"Ortez, C. et al. Cerebrospinal fluid synaptic proteins as useful biomarkers in tyrosine hydroxylase deficiency. Mol. Genet. Metab. 114, 34\u201340 (2015).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrneurol2015172_CR69","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/mds.870130507","volume":"13","author":"PJ Blanchet","year":"1998","unstructured":"Blanchet, P. J., Konitsiotis, S. & Chase, T. N. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord. 13, 798\u2013802 (1998).","journal-title":"Mov. Disord."},{"key":"BFnrneurol2015172_CR70","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejpn.2008.03.008","volume":"13","author":"HF Lee","year":"2009","unstructured":"Lee, H. F., Tsai, C. R., Chi, C. S., Chang, T. M. & Lee, H. J. Aromatic L-amino acid decarboxylase deficiency in Taiwan. Eur. J. Paediatr. Neurol. 13, 135\u2013140 (2009).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"BFnrneurol2015172_CR71","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/mds.25303","volume":"28","author":"M Mastrangelo","year":"2013","unstructured":"Mastrangelo, M., Caputi, C., Galosi, S., Giannini, M T. & Leuzzi, V. Transdermal rotigotine in the treatment of aromatic L-amino acid decarboxylase deficiency. Mov. Disord. 28, 556\u2013557 (2013).","journal-title":"Mov. Disord."},{"key":"BFnrneurol2015172_CR72","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1210\/jc.2013-2740","volume":"98","author":"JB Arnoux","year":"2013","unstructured":"Arnoux, J. B. et al. Aromatic L-amino acid decarboxylase deficiency is a cause of long-fasting hypoglycaemia. J. Clin. Endocrinol. Metab. 98, 4279\u20134284 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneurol2015172_CR73","first-page":"39","volume":"15","author":"V Leuzzi","year":"2015","unstructured":"Leuzzi, V. et al. Report of two never treated adult sisters with aromatic L-amino acid decarboxylase deficiency: a portrait of the natural history of the disease or an expanding phenotype? JIMD Rep. 15, 39\u201345 (2015).","journal-title":"JIMD Rep."},{"key":"BFnrneurol2015172_CR74","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cca.2014.01.034","volume":"431","author":"PW Chen","year":"2014","unstructured":"Chen, P. W. et al. Diagnosis of aromatic L-amino acid decarboxylase deficiency by measuring 3-O-methyldopa concentrations in dried blood spots. Clin. Chim. Acta 431, 19\u201322 (2014).","journal-title":"Clin. Chim. Acta"},{"key":"BFnrneurol2015172_CR75","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ymgme.2015.04.008","volume":"115","author":"PS Atwal","year":"2015","unstructured":"Atwal, P. S. et al. Aromatic L-amino acid decarboxylase deficiency diagnosed by clinical metabolomic profiling of plasma. Mol. Genet. Metab. 115, 91\u201394 (2015).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrneurol2015172_CR76","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/jnnp.53.7.569","volume":"53","author":"R Surtees","year":"1990","unstructured":"Surtees, R. & Hyland, K. L-3,4-dihydroxyphenylalanine (levodopa) lowers central nervous system S-adenosylmethionine concentrations in humans. J. Neurol. Neurosurg. Psychiatry 53, 569\u2013572 (1990).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2015172_CR77","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/ana.20055","volume":"55","author":"YT Chang","year":"2004","unstructured":"Chang, Y. T. et al. Levodopa-responsive aromatic L-amino acid decarboxylase deficiency. Ann. Neurol. 55, 435\u2013438 (2004).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2015172_CR78","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ymgme.2009.01.010","volume":"97","author":"GF Allen","year":"2009","unstructured":"Allen, G. F., Land, J. M. & Heales, S. J. A new perspective on the treatment of aromatic L-amino acid decarboxylase deficiency. Mol. Genet. Metab. 97, 6\u201314 (2009).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrneurol2015172_CR79","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10545-009-1076-1","volume":"32","author":"C Manegold","year":"2009","unstructured":"Manegold, C. et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J. Inherit. Metab. Dis. 32, 371\u2013380 (2009).","journal-title":"J. Inherit. Metab. Dis."},{"key":"BFnrneurol2015172_CR80","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1471-4159.2010.06742.x","volume":"114","author":"GF Allen","year":"2010","unstructured":"Allen, G. F. et al. Pyridoxal 5\u2032-phosphate deficiency causes a loss of aromatic L-amino acid decarboxylase in patients and human neuroblastoma cells, implications for aromatic L-amino acid decarboxylase and vitamin B6 deficiency states. J. Neurochem. 114, 87\u201396 (2010).","journal-title":"J. Neurochem."},{"key":"BFnrneurol2015172_CR81","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1212\/WNL.62.7.1058","volume":"62","author":"R Pons","year":"2004","unstructured":"Pons, R. et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment and prognosis. Neurology 62, 1058\u20131065 (2004).","journal-title":"Neurology"},{"key":"BFnrneurol2015172_CR82","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1212\/WNL.42.10.1980","volume":"42","author":"K Hyland","year":"1992","unstructured":"Hyland, K., Surtees, R A., Rodeck, C. & Clayton, P. T. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 42, 1980\u20131988 (1992).","journal-title":"Neurology"},{"key":"BFnrneurol2015172_CR83","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/088307389701200602","volume":"12","author":"A Maller","year":"1997","unstructured":"Maller, A., Hyland, K., Milstein, S., Biaggioni, I. & Butler, I. J. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second family. J. Child Neurol. 12, 349\u2013354 (1997).","journal-title":"J. Child Neurol."},{"issue":"Suppl. 6","key":"BFnrneurol2015172_CR84","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1002\/ana.10631","volume":"54","author":"KJ Swoboda","year":"2003","unstructured":"Swoboda, K. J., Saul, J. P., McKenna, C. E., Speller, N. B. & Hyland, K. Aromatic L-amino acid decarboxylase deficiency: overview of clinical features and outcomes. Ann. Neurol. 54 (Suppl. 6), S49\u2013S55 (2003).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2015172_CR85","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40272-014-0079-z","volume":"16","author":"J Ng","year":"2014","unstructured":"Ng, J., Heales, S. J. & Kurian, M. A. Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders. Paediatr. Drugs 16, 275\u2013291 (2014).","journal-title":"Paediatr. Drugs"},{"key":"BFnrneurol2015172_CR86","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40261-013-0150-5","volume":"34","author":"W Cawello","year":"2014","unstructured":"Cawello, W. et al. Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in health Japanese and Caucasian subjects. Clin. Drug Investig. 34, 95\u2013105 (2014).","journal-title":"Clin. Drug Investig."},{"key":"BFnrneurol2015172_CR87","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1093\/brain\/awq143","volume":"133","author":"PB Mills","year":"2010","unstructured":"Mills, P. B. et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain 133, 2148\u20132159 (2010).","journal-title":"Brain"},{"key":"BFnrneurol2015172_CR88","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/hmg\/ddi120","volume":"14","author":"PB Mills","year":"2005","unstructured":"Mills, P. B. et al. Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5\u2032-phosphate oxidase. Hum. Mol. Genet. 14, 1077\u20131086 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol2015172_CR89","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ajmg.b.32020","volume":"159B","author":"K Derwinska","year":"2012","unstructured":"Derwinska, K. et al. Clinical improvement of the aggressive neurobehavioral phenotype in a patient with a deletion of PITX3 and the absence of L-DOPA in the cerebrospinal fluid. Am. J. Med. Genet. B Neuropsychiatr. Genet. 159B, 236\u2013242 (2012).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"BFnrneurol2015172_CR90","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ymgme.2011.05.014","volume":"104","author":"S Stockler","year":"2011","unstructured":"Stockler, S. et al. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol. Genet. Metab. 104, 48\u201360 (2011).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrneurol2015172_CR91","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1073\/pnas.1101193108","volume":"108","author":"SD Reddy","year":"2011","unstructured":"Reddy, S. D. et al. Multiple coregulatory control of tyrosine hydroxylase gene transcription. Proc. Natl Acad. Sci. USA 108, 4200\u20134205 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2015172_CR92","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1523\/JNEUROSCI.3718-04.2005","volume":"25","author":"DY Hwang","year":"2005","unstructured":"Hwang, D. Y. et al. 3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J. Neurosci. 25, 2132\u20132137 (2005).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2015172_CR93","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0169-328X(03)00162-1","volume":"114","author":"DY Hwang","year":"2003","unstructured":"Hwang, D. Y., Ardayfio, P., Kang, U. J., Semina, E. V. & Kim, K. S. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res. Mol. Brain Res. 114, 123\u2013131 (2003).","journal-title":"Brain Res. Mol. Brain Res."},{"key":"BFnrneurol2015172_CR94","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1172\/JCI118492","volume":"97","author":"JW Lenders","year":"1996","unstructured":"Lenders, J. W. et al. Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. J. Clin. Invest. 97, 1010\u20131019 (1996).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol2015172_CR95","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ejmg.2012.01.007","volume":"55","author":"RE O'Leary","year":"2012","unstructured":"O'Leary, R. E. et al. De novo microdeletion of Xp11.3 exclusively encompassing the monoamine oxidase A and B genes in a male infant with episodic hypotonia: a genomics approach to personalized medicine. Eur. J. Med. Genet. 55, 349\u2013353 (2012).","journal-title":"Eur. J. Med. Genet."},{"key":"BFnrneurol2015172_CR96","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/JCP.0b013e31820469ea","volume":"31","author":"PK Gillman","year":"2011","unstructured":"Gillman. P. K. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J. Clin. Psychopharmacol. 31, 66\u201374 (2011).","journal-title":"J. Clin. Psychopharmacol."},{"key":"BFnrneurol2015172_CR97","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/ejhg.2010.41","volume":"18","author":"A Whibley","year":"2010","unstructured":"Whibley, A. et al. Deletion of MAOA and MAOB in a male patient causes severe developmental delay, intermittent hypotonia and stereotypical hand movements. Eur. J. Hum. Genet. 18, 1095\u20131099 (2010).","journal-title":"Eur. J. Hum. Genet."},{"key":"BFnrneurol2015172_CR98","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.braindev.2013.01.004","volume":"36","author":"M Saito","year":"2014","unstructured":"Saito, M. et al. MAOA\/B deletion syndrome in male siblings with severe developmental delay and sudden loss of muscle tonus. Brain Dev. 36, 64\u201369 (2014).","journal-title":"Brain Dev."},{"key":"BFnrneurol2015172_CR99","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/ajmg.1320420126","volume":"42","author":"FA Collins","year":"1992","unstructured":"Collins, F. A. et al. Clinical, biochemical, and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to a microdeletion Xp11.3 including the Norrie disease locus and monoamine oxidase (MAOA and MAOB) genes. Am. J. Med. Genet. 42, 127\u2013134 (1992).","journal-title":"Am. J. Med. Genet."},{"key":"BFnrneurol2015172_CR100","doi-asserted-by":"publisher","first-page":"39645","DOI":"10.1074\/jbc.M405550200","volume":"279","author":"K Chen","year":"2004","unstructured":"Chen, K., Holschneider, D. P., Wu, W., Rebrin, I. & Shih, J. C. A spontaneous point mutation produces monoamine oxidase A\/B knock-out mice with greatly elevated monoamines and anxiety-like behaviour. J. Biol. Chem. 279, 39645\u201339652 (2004).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2015172_CR101","volume-title":"GeneReviews","author":"D Robertson","year":"2013","unstructured":"Robertson, D. & Garland, E. M. Dopamine beta-hydroxylase deficiency. GeneReviews [online] (updated 2013)."},{"key":"BFnrneurol2015172_CR102","unstructured":"Wassenberg, T. et al. Clinical and biochemical characteristics of dopamine beta hydroxylase deficiency: expanding the clinical spectrum caused by norepinephrine and epinephrine deficiency [poster]. 4th International Symposium on Paediatric Movement Disorders P36 (2015)."},{"key":"BFnrneurol2015172_CR103","doi-asserted-by":"publisher","first-page":"S547","DOI":"10.1097\/00004872-198812040-00172","volume":"6","author":"AJ Man in 't Veld","year":"1988","unstructured":"Man in 't Veld, A. J. et al. dl-Threo-3,4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension in dopamine beta-hydroxylase deficiency. J. Hypertens. Suppl. 6, S547\u2013S549 (1988).","journal-title":"J. Hypertens. Suppl."},{"key":"BFnrneurol2015172_CR104","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/S0896-6273(00)80418-3","volume":"19","author":"EA Fon","year":"1997","unstructured":"Fon, E. A. et al. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19, 1271\u20131283 (1997).","journal-title":"Neuron"},{"key":"BFnrneurol2015172_CR105","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0031-6997(25)07428-9","volume":"11","author":"A Carlsson","year":"1959","unstructured":"Carlsson, A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev. 11, 490\u2013493 (1959).","journal-title":"Pharmacol. Rev."},{"key":"BFnrneurol2015172_CR106","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/dmcn.12116","volume":"55","author":"M Molero-Luis","year":"2013","unstructured":"Molero-Luis, M. et al. Homovanillic acid in cerebrospinal fluid of 1388 children with neurological disorders. Dev. Med. Child Neurol. 55, 559\u2013566 (2013).","journal-title":"Dev. Med. Child Neurol."},{"key":"BFnrneurol2015172_CR107","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1172\/JCI73778","volume":"124","author":"FH Hansen","year":"2014","unstructured":"Hansen, F. H. et al. Missense dopamine transporter mutations associated with adult parkinsonism and ADHD. J. Clin. Invest. 124, 3107\u20133120 (2014).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol2015172_CR108","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/brain\/awu056","volume":"137","author":"KP Bhatia","year":"2014","unstructured":"Bhatia, K. P. 'That DAT'gene that causes dystonia-parkinsonism: broadening the phenotype. Brain 137, 976\u2013977 (2014).","journal-title":"Brain"},{"key":"BFnrneurol2015172_CR109","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/j.1469-8749.2007.00740.x","volume":"49","author":"A Garc\u00eda-Cazorla","year":"2007","unstructured":"Garc\u00eda-Cazorla, A. et al. Secondary abnormalities of neurotransmitters in infants with neurological disorders. Dev. Med. Child Neurol. 49, 740\u2013744 (2007).","journal-title":"Dev. Med. Child Neurol."},{"key":"BFnrneurol2015172_CR110","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.clinbiochem.2008.08.077","volume":"41","author":"I Mar\u00edn-Valencia","year":"2008","unstructured":"Mar\u00edn-Valencia, I. et al. Biochemical diagnosis of dopaminergic disturbances in paediatric patients: analysis of cerebrospinal fluid homovanillic acid and other biogenic amines. Clin. Biochem. 41, 1306\u20131315 (2008).","journal-title":"Clin. Biochem."},{"key":"BFnrneurol2015172_CR111","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.braindev.2007.06.009","volume":"30","author":"S Duarte","year":"2008","unstructured":"Duarte, S. et al. Cerebrospinal fluid pterins and neurotransmitters in early severe epileptic encephalopathies. Brain Dev. 30, 106\u2013111 (2008).","journal-title":"Brain Dev."},{"key":"BFnrneurol2015172_CR112","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13023-015-0234-9","volume":"10","author":"S Mericmek-Mahmutoglu","year":"2015","unstructured":"Mericmek-Mahmutoglu, S. et al. Prevalence of inherited neurotransmitter disorders in patients with movement disorders and epilepsy: a retrospective cohort study. Orphanet J. Rare Dis. 10, 12 (2015).","journal-title":"Orphanet J. Rare Dis."},{"key":"BFnrneurol2015172_CR113","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s10545-010-9200-9","volume":"33","author":"E De Grandis","year":"2010","unstructured":"De Grandis, E. et al. Cerebrospinal fluid alterations of the serotonin product, 5-hydroxyindolacetic acid, in neurological disorders. J. Inherit. Metab. Dis. 33, 803\u2013809 (2010).","journal-title":"J. Inherit. Metab. Dis."},{"key":"BFnrneurol2015172_CR114","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/BF01291793","volume":"103","author":"M Naumann","year":"1996","unstructured":"Naumann, M., G\u00f6tz, M., Reiners, K., Lange, K. W. & Riederer, P. Neurotransmitters in CSF of idiopathic adult-onset dystonia: reduced 5-HIAA levels as evidence of impaired serotonergic metabolism. J. Neural Transm. 103, 1083\u20131091 (1996).","journal-title":"J. Neural Transm."},{"key":"BFnrneurol2015172_CR115","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1203\/00006450-200207000-00017","volume":"52","author":"B Assmann","year":"2002","unstructured":"Assmann, B., K\u00f6hler, M., Hoffmann, G. F., Heales, S. & Surtees, R. Selective decrease in central nervous system serotonin turnover in children with dopa-nonresponsive dystonia. Pediatr. Res. 52, 91\u201394 (2002).","journal-title":"Pediatr. Res."},{"key":"BFnrneurol2015172_CR116","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10545-014-9697-4","volume":"37","author":"C Marecos","year":"2014","unstructured":"Marecos, C., Ng, J., Kurian, M. A. What is new for monoamine neurotransmitter disorders? J. Inherit. Metab. Dis. 37, 619\u2013626 (2014).","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl. S1","key":"BFnrneurol2015172_CR117","first-page":"16","volume":"55","author":"J Ng","year":"2013","unstructured":"Ng, J. et al. TH gene-negative infantile onset severe dopamine deficiency syndrome: a novel neurotransmitter disorder? [abstract]. Dev. Med. Child. Neurol. 55 (Suppl. S1), 16 (2013).","journal-title":"Dev. Med. Child. Neurol."},{"key":"BFnrneurol2015172_CR118","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.pediatrneurol.2011.08.009","volume":"45","author":"MM Moran","year":"2011","unstructured":"Moran, M. M., Allen, N. M, Treacy, E. P. & King, M. D. \u201cStiff neonate\u201d with mitochondrial DNA depletion and secondary neurotransmitter defects. Pediatr. Neurol. 45, 403\u2013405 (2011).","journal-title":"Pediatr. Neurol."},{"key":"BFnrneurol2015172_CR119","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1016\/S0021-9258(19)39752-2","volume":"265","author":"ER Werner","year":"1990","unstructured":"Werner, E. R. et al. Tetrahydrobiopterin biosynthesic activities in human macrophages, fibroblasts, THP-1 and T-24 cells. J. Biol. Chem. 265, 3189\u20133192 (1990).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2015172_CR120","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/clinchem\/44.1.161","volume":"44","author":"MM Millner","year":"1998","unstructured":"Millner, M. M. et al. Neopterin concentrations in cerebrospinal fluid and serum as an aid in differentiating central nervous system and peripheral infections in children. Clin. Chem. 44, 161\u2013167 (1998).","journal-title":"Clin. Chem."},{"key":"BFnrneurol2015172_CR121","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1742-6405-7-15","volume":"7","author":"L Hagberg","year":"2010","unstructured":"Hagberg, L. et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res. Ther. 7, 15 (2010).","journal-title":"AIDS Res. Ther."},{"key":"BFnrneurol2015172_CR122","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S1474-4422(13)70258-8","volume":"12","author":"GI Rice","year":"2013","unstructured":"Rice, G. I. et al. Assessment of interferon-related biomarkers in Aicardi-Gouti\u00e8res syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 12, 1159\u20131169 (2013).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2015172_CR123","doi-asserted-by":"publisher","first-page":"E232","DOI":"10.1073\/pnas.1104699108","volume":"108","author":"M du Moulian","year":"2011","unstructured":"du Moulian, M., N\u00fcrnberg, P., Crow, Y. J. & Rutsch, F. Cerebral vasculopathy is a common feature in Aicardi-Gouti\u00e8res syndrome associated with SAMHD1 mutations. Proc. Natl Acad. Sci. USA 108, E232 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2015172_CR124","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/jmedgenet-2013-102038","volume":"51","author":"JH Livingston","year":"2014","unstructured":"Livingston, J. H. et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J. Med. Genet. 51, 76\u201382 (2014).","journal-title":"J. Med. Genet."},{"key":"BFnrneurol2015172_CR125","volume-title":"GeneReviews","author":"YJ Crow","year":"2014","unstructured":"Crow, Y. J. Aicardi-Gouti\u00e8res syndrome. GeneReviews [online] (updated 2014)."},{"key":"BFnrneurol2015172_CR126","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1212\/01.WNL.0000082726.08631.E7","volume":"61","author":"N Blau","year":"2003","unstructured":"Blau, N. et al. Cerebrospinal fluid pterins and folates in Aicardi-Gouti\u00e8res syndrome: a new phenotype. Neurology 61, 642\u2013647 (2003).","journal-title":"Neurology"},{"key":"BFnrneurol2015172_CR127","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/dmcn.12130","volume":"55","author":"MA Kurian","year":"2013","unstructured":"Kurian, M. A. What is the role of dopamine in childhood neurological disorders? Dev. Med. Child Neurol. 55, 493\u2013494 (2013).","journal-title":"Dev. Med. Child Neurol."},{"key":"BFnrneurol2015172_CR128","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.gene.2015.01.026","volume":"559","author":"C Graziano","year":"2015","unstructured":"Graziano, C. et al. Syndromic intellectual disability: a new phenotype caused by an aromatic amino acid decarboxylase gene (DDC) variant. Gene 559, 144\u2013148 (2015).","journal-title":"Gene"},{"key":"BFnrneurol2015172_CR129","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.1093\/hmg\/ddu266","volume":"23","author":"R Montioli","year":"2014","unstructured":"Montioli, R. et al. A comprehensive picture of the mutations associated with aromatic amino acid decarboxylase deficiency, from molecular mechanisms to therapy implications. Hum. Mol. Genet. 23, 5429\u20135440 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol2015172_CR130","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.stem.2011.01.013","volume":"8","author":"HN Nguyen","year":"2011","unstructured":"Nguyen, H. N. et al., LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell. 8, 267\u2013280 (2011).","journal-title":"Cell Stem Cell."},{"key":"BFnrneurol2015172_CR131","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.stem.2013.01.008","volume":"7","author":"P Reinhardt","year":"2013","unstructured":"Reinhardt, P. et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell. 7, 354\u2013367 (2013).","journal-title":"Cell Stem Cell."},{"key":"BFnrneurol2015172_CR132","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature12517","volume":"501","author":"MA Lancaster","year":"2013","unstructured":"Lancaster, M. A. et al. Cerebral organoids model human brain development and microcephaly. Nature 501, 373\u2013379 (2013).","journal-title":"Nature"},{"key":"BFnrneurol2015172_CR133","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nbt.2501","volume":"31","author":"WY Hwang","year":"2013","unstructured":"Hwang, W. Y. et al. Efficient genome editing in zebrafish using a CRISPR\u2013Cas system. Nat. Biotechnol. 31, 227\u2013229 (2013).","journal-title":"Nat. Biotechnol."},{"key":"BFnrneurol2015172_CR134","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nbt.2661","volume":"31","author":"D Li","year":"2013","unstructured":"Li, D. et al. Heritable gene targeting in the mouse and rat using a CRISPR\u2013Cas system. Nat. Biotechnol. 31, 681\u2013683 (2013).","journal-title":"Nat. Biotechnol."},{"key":"BFnrneurol2015172_CR135","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/humu.21529","volume":"32","author":"S Brasil","year":"2011","unstructured":"Brasil, S. et al. Pseudoexon exclusion by antisense therapy in 6-pyruvoyl-tetrahydropterin synthase deficiency. Hum. Mutat. 32, 1019\u20131027 (2011).","journal-title":"Hum. Mutat."},{"key":"BFnrneurol2015172_CR136","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","volume":"70","author":"JL Eberling","year":"2008","unstructured":"Eberling, J. L. et al. Results from phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70, 1980\u20131983 (2008).","journal-title":"Neurology"},{"key":"BFnrneurol2015172_CR137","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","volume":"383","author":"S Palfi","year":"2014","unstructured":"Palfi, S. et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1\/2 trial. Lancet 383, 1138\u20131146 (2014).","journal-title":"Lancet"},{"key":"BFnrneurol2015172_CR138","doi-asserted-by":"publisher","first-page":"134ra61","DOI":"10.1126\/scitranslmed.3003640","volume":"4","author":"WL Hwu","year":"2012","unstructured":"Hwu, W. L. et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci. Transl. Med. 4, 134ra61 (2012).","journal-title":"Sci. Transl. Med."},{"key":"BFnrneurol2015172_CR139","doi-asserted-by":"publisher","unstructured":"Lee, N. C. et al. Benefits of neuronal preferential systemic gene therapy for neurotransmitter deficiency. Mol. Ther. http:\/\/dx.doi.org\/10.1038\/mt.2015.122 (2015).","DOI":"10.1038\/mt.2015.122"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2015.172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2015.172","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2015.172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T15:08:15Z","timestamp":1748617695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2015.172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,22]]},"references-count":139,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["BFnrneurol2015172"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2015.172","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,22]]},"assertion":[{"value":"22 September 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}